½ÉÀå ÆßÇÁ µð¹ÙÀ̽º ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® ¸®Æ÷Æ® : À¯Çüº°, Á¦Ç°º°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°, ºÎ¹® ¿¹Ãø(2025-2030³â)
Heart Pump Device Market Size, Share & Trends Analysis Report By Type, By Product (Ventricular Assist Devices, Intra-Aortic Balloon Pumps, Extracorporeal Membrane Oxygenation), By End-use, By Region, And Segment Forecasts, 2025 - 2030
»óǰÄÚµå
:
1750854
¸®¼Ä¡»ç
:
Grand View Research, Inc.
¹ßÇàÀÏ
:
2025³â 05¿ù
ÆäÀÌÁö Á¤º¸
:
¿µ¹® 120 Pages
¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
½ÉÀå ÆßÇÁ µð¹ÙÀ̽º ½ÃÀåÀÇ ¼ºÀå°ú µ¿Çâ :
Grand View Research, Inc.ÀÇ ÃֽЏ®Æ÷Æ®¿¡ µû¸£¸é ¼¼°èÀÇ ½ÉÀå ÆßÇÁ µð¹ÙÀ̽º ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 63¾ï 9,000¸¸ ´Þ·¯¿¡ ´ÞÇϸç, 2025-2030³â¿¡ 13.6%ÀÇ CAGR·Î È®´ëÇÒ °ÍÀ¸·Î ÃßÁ¤µÇ°í ÀÖ½À´Ï´Ù.
°ü»óµ¿¸ÆÁúȯ, ÇãÇ÷¼º ½ÉÀåÁúȯ ¹× ±âŸ CVD ÁúȯÀÇ À¯º´·ü Áõ°¡´Â ½ÉÀå ÆßÇÁ µð¹ÙÀ̽º¿¡ ´ëÇÑ ¼ö¿ä¸¦ Áõ°¡½Ãų °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¿¹¸¦ µé¾î ¿µ±¹ ½ÉÀå Àç´Ü(British Heart Foundation)ÀÌ ¹ßÇ¥ÇÑ ÀÚ·á¿¡ µû¸£¸é 2022³â ¿µ±¹¿¡¼ ¾à 760¸¸ ¸íÀÌ ½ÉÀ庴À» ¾Î°í ÀÖÀ¸¸ç, ¸Å³â ¾à 16¸¸ ¸íÀÌ CVD ¹× ±âŸ ½ÉÀå °ü·Ã ÁúȯÀ¸·Î »ç¸ÁÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¶ÇÇÑ 2020³â ¼¼°èº¸°Ç±â±¸(WHO) µ¥ÀÌÅÍ¿¡ µû¸£¸é ÀϺ»¿¡¼´Â °ü»óµ¿¸Æ¼º ½ÉÀåÁúȯÀ¸·Î 16¸¸ 3,905¸íÀÌ »ç¸ÁÇßÀ¸¸ç, ±× Áß ³úÁ¹ÁßÀ¸·Î ÀÎÇÑ »ç¸ÁÀÚ´Â 12¸¸ 1,823¸í(11.03%)¿¡ ´ÞÇß½À´Ï´Ù.
¶ÇÇÑ Áúº´ ÀÎ½Ä °³¼±À» À§ÇÑ Áö¿ø°ú ÀÎ½Ä °³¼± Ȱµ¿ Áõ°¡·Î ÀÎÇØ ½ÃÀåÀÌ ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¿¹¸¦ µé¾î 2022³â 1¿ù IIT KanpurÀÇ The School of Medical Research and Technology´Â °úÁ¦ ±â¹Ý ÇÁ·Î±×·¥ÀÎ Hridyantra¸¦ ½ÃÀÛÇß½À´Ï´Ù. Hridyantra´Â ¸»±â ½ÉºÎÀü(HF) ȯÀÚ¸¦ À§ÇØ ÁÂ½É½Ç º¸Á¶ Àåºñ(LVAD)¶ó°í ºÒ¸®´Â ÷´Ü Àΰø ½ÉÀåÀ» ¸¸µå´Â °ÍÀÌ ¸ñÀûÀ̸ç, HF ȯÀÚ°¡ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â Ä¡·á¹ýÀ» °³¼±ÇÏ´Â °ÍÀ» ¸ñÇ¥·Î Çϰí ÀÖ½À´Ï´Ù. ÀÌ ÇÁ·Î±×·¥À» ÅëÇØ HF ȯÀÚ°¡ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â Ä¡·á ¿É¼ÇÀÌ Å©°Ô °³¼±µÇ¾î ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀÌ µÉ °ÍÀ¸·Î ±â´ëµË´Ï´Ù.
½ÉÀå ÆßÇÁ µð¹ÙÀ̽º ½ÃÀå º¸°í¼ ÇÏÀ̶óÀÌÆ®
- À¯Çüº°·Î´Â À̽ÄÇü ½ÉÀå ÆßÇÁ µð¹ÙÀ̽º ºÎ¹®ÀÌ 2024³â ½ÃÀåÀÇ 69.1%·Î ÃÖ´ë ¸ÅÃâ Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ÀÌ´Â Ç÷¾× °ø±ÞÀ» µ½°í, À̽ÄÀ» À§ÇÑ °¡±³ ¿ªÇÒÀ» Çϸç, ½É¹æ¼¼µ¿ ȯÀÚÀÇ ¿µ±¸ÀûÀÎ Ä¡·á ¿É¼ÇÀ¸·Î ÀÛ¿ëÇϱ⠶§¹®ÀÔ´Ï´Ù.
- Á¦Ç°º°·Î´Â ½É½Çº¸Á¶ÀåÄ¡(VAD)(VAD)ÀÌ 2024³â 68.5%ÀÇ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ¿¹Ãø ±â°£ Áß CAGRÀº 14.8%·Î °¡Àå ºü¸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Àü ¼¼°è¿¡¼ ½É¹æ¼¼µ¿ À¯º´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ½É½Çº¸Á¶ÀåÄ¡(VAD)¿¡ ´ëÇÑ ¼ö¿ä´Â ¿¹Ãø ±â°£ Áß ºü¸£°Ô Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
- ÃÖÁ¾ ¿ëµµº°·Î´Â º´¿ø ºÎ¹®ÀÌ 2024³â ½ÃÀåÀ» Àå¾ÇÇß½À´Ï´Ù.
- ºÏ¹Ì´Â ³ôÀº ½ÉºÎÀü À¯º´·ü, °í·ÉÈ Àα¸ Áõ°¡, źźÇÑ ÀÇ·á ½Ã½ºÅÛÀ¸·Î ÀÎÇØ 2024³â 52.59% ÀÌ»óÀÇ ¸ÅÃâ Á¡À¯À²·Î ½ÃÀåÀ» Àå¾ÇÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
¸ñÂ÷
Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§
Á¦2Àå °³¿ä
Á¦3Àå ½ÉÀå ÆßÇÁ µð¹ÙÀ̽º ½ÃÀåÀÇ º¯¼ö, µ¿Çâ, ¹üÀ§
- ½ÃÀå °èÅë Àü¸Á
- ¸ð½ÃÀå Àü¸Á
- °ü·Ã/ºÎ¼ö ½ÃÀå Àü¸Á
- ½ÃÀå ¿ªÇÐ
- ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ºÐ¼®
- ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
- ½ÉÀå ÆßÇÁ µð¹ÙÀ̽º ½ÃÀå ºÐ¼® Åø
- ¾÷°è ºÐ¼® - PorterÀÇ »ê¾÷ ºÐ¼®
- PESTEL ºÐ¼®
- ½ÉÀå ÆßÇÁ µð¹ÙÀ̽º ½ÃÀå : ÆÄÀÌÇÁ¶óÀÎ ºÐ¼®
Á¦4Àå ½ÉÀå ÆßÇÁ µð¹ÙÀ̽º ½ÃÀå : À¯Çü ÃßÁ¤¡¤µ¿Ç⠺м®
- À¯Çü ºÎ¹® ´ë½Ãº¸µå
- ½ÉÀå ÆßÇÁ µð¹ÙÀ̽º ½ÃÀå : À¯Çü º¯µ¿ ºÐ¼®
- ¼¼°èÀÇ ½ÉÀå ÆßÇÁ µð¹ÙÀ̽º ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м®(À¯Çüº°, 2018-2030³â)
- À̽ÄÇü ½ÉÀå ÆßÇÁ µð¹ÙÀ̽º
- ü¿Ü ½ÉÀå ÆßÇÁ µð¹ÙÀ̽º
Á¦5Àå ½ÉÀå ÆßÇÁ µð¹ÙÀ̽º ½ÃÀå : Á¦Ç° ÃßÁ¤¡¤µ¿Ç⠺м®
- Á¦Ç° ºÎ¹® ´ë½Ãº¸µå
- ½ÉÀå ÆßÇÁ µð¹ÙÀ̽º ½ÃÀå : Á¦Ç° º¯µ¿ ºÐ¼®
- ¼¼°èÀÇ ½ÉÀå ÆßÇÁ µð¹ÙÀ̽º ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м®(Á¦Ç°º°, 2018-2030³â)
- ½É½Ç º¸Á¶ ±â±â(VAD)
- ÁÂ½Ç º¸Á¶ ±â±â(LVAD)
- ¿ì½Ç º¸Á¶ ±â±â(RVAD)
- ¾ç½É½Ç º¸Á¶ ±â±â(BiVAD)
- °æÇÇÀû ½É½Ç º¸Á¶ ±â±â(PVAD)
- ´ëµ¿¸Æ³» dz¼± ÆßÇÁ(IABP)
- ü¿Ü½Ä ¸·Çü ÀΰøÆó(ECMO)
Á¦6Àå ½ÉÀå ÆßÇÁ µð¹ÙÀ̽º ½ÃÀå : ÃÖÁ¾ ¿ëµµ ÃßÁ¤¡¤µ¿Ç⠺м®
- ÃÖÁ¾ ¿ëµµ ºÎ¹® ´ë½Ãº¸µå
- ½ÉÀå ÆßÇÁ µð¹ÙÀ̽º ½ÃÀå : ÃÖÁ¾ ¿ëµµ º¯µ¿ ºÐ¼®
- ¼¼°èÀÇ ½ÉÀå ÆßÇÁ µð¹ÙÀ̽º ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м®(ÃÖÁ¾ ¿ëµµº°, 2018-2030³â)
- º´¿ø
- ½ÉÀå ¼¾ÅÍ
- ¿¬±¸±â°ü
Á¦7Àå ½ÉÀå ÆßÇÁ µð¹ÙÀ̽º ½ÃÀå : Áö¿ª ÃßÁ¤¡¤µ¿Ç⠺м®
- Áö¿ª ½ÃÀå ´ë½Ãº¸µå
- Áö¿ªº° ½ÃÀå Á¡À¯À² ºÐ¼®, 2024³â ¹× 2030³â
- Áö¿ªº° ½ÃÀå : ÁÖ¿ä Æ÷ÀÎÆ®
- ºÏ¹Ì
- À¯·´
- ¿µ±¹
- µ¶ÀÏ
- ÇÁ¶û½º
- ÀÌÅ»¸®¾Æ
- ½ºÆäÀÎ
- ³ë¸£¿þÀÌ
- ½º¿þµ§
- µ§¸¶Å©
- ¾Æ½Ã¾ÆÅÂÆò¾ç
- ÀϺ»
- Áß±¹
- Àεµ
- È£ÁÖ
- Çѱ¹
- ű¹
- ¶óƾ¾Æ¸Þ¸®Ä«
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
- ³²¾ÆÇÁ¸®Ä«°øÈ±¹
- »ç¿ìµð¾Æ¶óºñ¾Æ
- ¾Æ¶ø¿¡¹Ì¸®Æ®
- Äí¿þÀÌÆ®
Á¦8Àå °æÀï ±¸µµ
- ÁÖ¿ä ½ÃÀå Âü¿© ±â¾÷¿¡ ÀÇÇÑ ÃÖ±Ù µ¿Çâ°ú ¿µÇ⠺м®
- ±â¾÷/°æÀï ºÐ·ù
- º¥´õ ±¸µµ
- ±â¾÷ °³¿ä
- Abbott
- ABIOMED(Johnson &Johnson Services, Inc.)
- Getinge
- LivaNova PLC
- Berlin Heart
- Picard Medical, Inc.(SynCardia Systems, LLC)
- Jarvik Heart, Inc
- BiVACOR Inc.
- Leviticus Cardio
- Teleflex Incorporated
KSA
¿µ¹® ¸ñÂ÷
Heart Pump Device Market Growth & Trends:
The global heart pump device market size is estimated to reach USD 6.39 billion by 2030, expanding at a CAGR of 13.6 % from 2025 to 2030, according to a new report by Grand View Research, Inc. The growing prevalence of coronary artery disease, ischemic heart disease, and other CVD diseases is anticipated to boost the demand for heart pump devices. For instance, according to data published by British Heart Foundation, in 2022, about 7.6 million individuals in the UK live with heart disease, and each year, around 160,000 people die from CVD and other heart-related conditions in the UK. Moreover, according to WHO data in 2020, coronary heart disease caused 163,905 deaths in Japan, with 121,823 or 11.03% of total deaths were caused due to stroke.
Furthermore, the market is anticipated to grow by increasing support and awareness initiatives for disease awareness. For instance, in January 2022, The School of Medical Research and Technology at IIT Kanpur launched Hridyantra, a challenge-based program. Its objective is to create an advanced artificial heart called a Left Ventricular Assist Device (LVAD) for patients with end-stage heart failure (HF). Hridyantra aims to improve the available treatment options for HF patients. This program is expected to significantly improve the treatment options available for patients with HF, thereby driving market growth.
Heart Pump Device Market Report Highlights:
- Based on type, the implanted heart pump devices segment accounted for the largest revenue share of 69.1% of the market in 2024, due to their ability to assist with pumping blood and serve as a bridge to transplantation or a permanent therapy option for HF patients.
- Based on product, ventricular assist devices (VADs) held the largest market share of 68.5 % in 2024. It is estimated to register the fastest CAGR of 14.8% during the forecast period; owing to the increasing prevalence of HF worldwide, the demand for VADs is anticipated to grow rapidly over the forecast period.
- Based on end-use, the hospital segment dominated the market in 2024, attributed to the high number of surgeries performed in hospitals.
- North America is expected to dominate the market with over 52.59% revenue share in 2024 due to the high prevalence of heart failure, growing aging population, and robust healthcare system.
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Type
- 1.2.2. Product
- 1.2.3. End Use
- 1.2.4. Regional scope
- 1.2.5. Estimates and forecasts timeline
- 1.3. Research Methodology
- 1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR's internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.4.5. Details of primary research
- 1.5. Information or Data Analysis
- 1.5.1. Data analysis models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
- 1.8. List of Secondary Sources
- 1.9. List of Primary Sources
- 1.10. Objectives
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Type Segment
- 2.2.2. Product Segment
- 2.2.3. End Use Segment
- 2.2.4. Regional outlook
- 2.3. Competitive Insights
Chapter 3. Heart Pump Device Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Market Dynamics
- 3.2.1. Market driver analysis
- 3.2.2. Market restraint analysis
- 3.3. Heart Pump Device Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's
- 3.3.1.1. Supplier power
- 3.3.1.2. Buyer power
- 3.3.1.3. Substitution threat
- 3.3.1.4. Threat of new entrant
- 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
- 3.3.2.1. Political landscape
- 3.3.2.2. Technological landscape
- 3.3.2.3. Economic landscape
- 3.4. Heart Pump Device Market: Pipeline Analysis
Chapter 4. Heart Pump Device Market: Type Estimates & Trend Analysis
- 4.1. Type Segment Dashboard
- 4.2. Heart Pump Device Market: Type Movement Analysis
- 4.3. Global Heart Pump Device Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
- 4.4. Implanted Heart Pump Devices
- 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 4.5. Extracorporeal Heart Pump Devices
- 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 5. Heart Pump Device Market: Product Estimates & Trend Analysis
- 5.1. Product Segment Dashboard
- 5.2. Heart Pump Device Market: Product Movement Analysis
- 5.3. Global Heart Pump Device Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
- 5.4. Ventricular Assist Devices (VADs)
- 5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.4.2. Left Ventricular Assist Devices (LVAD)
- 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.4.3. Right Ventricular Assist Devices (RVAD)
- 5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.4.4. Bi-Ventricular Assist Devices (BiVAD)
- 5.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.4.5. Percutaneous Ventricular Assist Devices (PVAD)
- 5.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.5. Intra-Aortic Balloon Pumps (IABPs)
- 5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.6. Extracorporeal Membrane Oxygenation (ECMO)
- 5.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 6. Heart Pump Device Market: End Use Estimates & Trend Analysis
- 6.1. End Use Segment Dashboard
- 6.2. Heart Pump Device Market: End Use Movement Analysis
- 6.3. Global Heart Pump Device Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
- 6.4. Hospitals
- 6.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 6.5. Cardiac Centers
- 6.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 6.6. Research Institute
- 6.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 7. Heart Pump Device Market: Regional Estimates & Trend Analysis
- 7.1. Regional Market Dashboard
- 7.2. Regional Market Share Analysis, 2024 & 2030
- 7.3. Continuous bioprocessing market by Region: Key Takeaways
- 7.4. North America
- 7.4.1. U.S.
- 7.4.1.1. Key country dynamics
- 7.4.1.2. Regulatory framework/ reimbursement structure
- 7.4.1.3. Competitive scenario
- 7.4.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
- 7.4.2. Canada
- 7.4.2.1. Key country dynamics
- 7.4.2.2. Regulatory framework/ reimbursement structure
- 7.4.2.3. Competitive scenario
- 7.4.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
- 7.4.3. Mexico
- 7.4.3.1. Key country dynamics
- 7.4.3.2. Regulatory framework/ reimbursement structure
- 7.4.3.3. Competitive scenario
- 7.4.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5. Europe
- 7.5.1. UK
- 7.5.1.1. Key country dynamics
- 7.5.1.2. Regulatory framework/ reimbursement structure
- 7.5.1.3. Competitive scenario
- 7.5.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.2. Germany
- 7.5.2.1. Key country dynamics
- 7.5.2.2. Regulatory framework/ reimbursement structure
- 7.5.2.3. Competitive scenario
- 7.5.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.3. France
- 7.5.3.1. Key country dynamics
- 7.5.3.2. Regulatory framework/ reimbursement structure
- 7.5.3.3. Competitive scenario
- 7.5.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.4. Italy
- 7.5.4.1. Key country dynamics
- 7.5.4.2. Regulatory framework/ reimbursement structure
- 7.5.4.3. Competitive scenario
- 7.5.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.5. Spain
- 7.5.5.1. Key country dynamics
- 7.5.5.2. Regulatory framework/ reimbursement structure
- 7.5.5.3. Competitive scenario
- 7.5.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.6. Norway
- 7.5.6.1. Key country dynamics
- 7.5.6.2. Regulatory framework/ reimbursement structure
- 7.5.6.3. Competitive scenario
- 7.5.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.7. Sweden
- 7.5.7.1. Key country dynamics
- 7.5.7.2. Regulatory framework/ reimbursement structure
- 7.5.7.3. Competitive scenario
- 7.5.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.8. Denmark
- 7.5.8.1. Key country dynamics
- 7.5.8.2. Regulatory framework/ reimbursement structure
- 7.5.8.3. Competitive scenario
- 7.5.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
- 7.6. Asia Pacific
- 7.6.1. Japan
- 7.6.1.1. Key country dynamics
- 7.6.1.2. Regulatory framework/ reimbursement structure
- 7.6.1.3. Competitive scenario
- 7.6.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
- 7.6.2. China
- 7.6.2.1. Key country dynamics
- 7.6.2.2. Regulatory framework/ reimbursement structure
- 7.6.2.3. Competitive scenario
- 7.6.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
- 7.6.3. India
- 7.6.3.1. Key country dynamics
- 7.6.3.2. Regulatory framework/ reimbursement structure
- 7.6.3.3. Competitive scenario
- 7.6.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
- 7.6.4. Australia
- 7.6.4.1. Key country dynamics
- 7.6.4.2. Regulatory framework/ reimbursement structure
- 7.6.4.3. Competitive scenario
- 7.6.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
- 7.6.5. South Korea
- 7.6.5.1. Key country dynamics
- 7.6.5.2. Regulatory framework/ reimbursement structure
- 7.6.5.3. Competitive scenario
- 7.6.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
- 7.6.6. Thailand
- 7.6.6.1. Key country dynamics
- 7.6.6.2. Regulatory framework/ reimbursement structure
- 7.6.6.3. Competitive scenario
- 7.6.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
- 7.7. Latin America
- 7.7.1. Brazil
- 7.7.1.1. Key country dynamics
- 7.7.1.2. Regulatory framework/ reimbursement structure
- 7.7.1.3. Competitive scenario
- 7.7.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
- 7.7.2. Argentina
- 7.7.2.1. Key country dynamics
- 7.7.2.2. Regulatory framework/ reimbursement structure
- 7.7.2.3. Competitive scenario
- 7.7.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
- 7.8. MEA
- 7.8.1. South Africa
- 7.8.1.1. Key country dynamics
- 7.8.1.2. Regulatory framework/ reimbursement structure
- 7.8.1.3. Competitive scenario
- 7.8.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
- 7.8.2. Saudi Arabia
- 7.8.2.1. Key country dynamics
- 7.8.2.2. Regulatory framework/ reimbursement structure
- 7.8.2.3. Competitive scenario
- 7.8.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
- 7.8.3. UAE
- 7.8.3.1. Key country dynamics
- 7.8.3.2. Regulatory framework/ reimbursement structure
- 7.8.3.3. Competitive scenario
- 7.8.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
- 7.8.4. Kuwait
- 7.8.4.1. Key country dynamics
- 7.8.4.2. Regulatory framework/ reimbursement structure
- 7.8.4.3. Competitive scenario
- 7.8.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 8. Competitive Landscape
- 8.1. Recent Developments & Impact Analysis, By Key Market Participants
- 8.2. Company/Competition Categorization
- 8.3. Vendor Landscape
- 8.3.1. Key company heat map analysis, 2024
- 8.4. Company Profiles
- 8.4.1. Abbott
- 8.4.1.1. Company overview
- 8.4.1.2. Financial performance
- 8.4.1.3. Product benchmarking
- 8.4.1.4. Strategic initiatives
- 8.4.2. ABIOMED (Johnson & Johnson Services, Inc.)
- 8.4.2.1. Company overview
- 8.4.2.2. Financial performance
- 8.4.2.3. Product benchmarking
- 8.4.2.4. Strategic initiatives
- 8.4.3. Getinge
- 8.4.3.1. Company overview
- 8.4.3.2. Financial performance
- 8.4.3.3. Product benchmarking
- 8.4.3.4. Strategic initiatives
- 8.4.4. LivaNova PLC
- 8.4.4.1. Company overview
- 8.4.4.2. Financial performance
- 8.4.4.3. Product benchmarking
- 8.4.4.4. Strategic initiatives
- 8.4.5. Berlin Heart
- 8.4.5.1. Company overview
- 8.4.5.2. Financial performance
- 8.4.5.3. Product benchmarking
- 8.4.5.4. Strategic initiatives
- 8.4.6. Picard Medical, Inc. (SynCardia Systems, LLC)
- 8.4.6.1. Company overview
- 8.4.6.2. Financial performance
- 8.4.6.3. Product benchmarking
- 8.4.6.4. Strategic initiatives
- 8.4.7. Jarvik Heart, Inc
- 8.4.7.1. Company overview
- 8.4.7.2. Financial performance
- 8.4.7.3. Product benchmarking
- 8.4.7.4. Strategic initiatives
- 8.4.8. BiVACOR Inc.
- 8.4.8.1. Company overview
- 8.4.8.2. Financial performance
- 8.4.8.3. Product benchmarking
- 8.4.8.4. Strategic initiatives
- 8.4.9. Leviticus Cardio
- 8.4.9.1. Company overview
- 8.4.9.2. Financial performance
- 8.4.9.3. Product benchmarking
- 8.4.9.4. Strategic initiatives
- 8.4.10. Teleflex Incorporated
- 8.4.10.1. Company overview
- 8.4.10.2. Financial performance
- 8.4.10.3. Product benchmarking
- 8.4.10.4. Strategic initiatives
°ü·ÃÀÚ·á